肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制

2019-06-03 QQ MedSci原创

PD-L1ALK间变性大细胞淋巴瘤免疫逃逸
关注

以PD1/PR-L1为基础的免疫疗法的成功强调了PD-L1在肿瘤进展中的重要作用，并提示我们急需通过深入了解PD-L1的表达调控机制，来开发新的方法以减弱PF-L1的功能。ALK阳性的间变性大细胞淋巴瘤（ALK+ ALCL）由于ALK活性下游多条成瘤信号通路组成性激活而表达较高水平的PD-L1，使其成为研究肿瘤细胞中与PD-L1上调相关的信号通路的一个很好的模型。研究人员通过CRISPR/Cas9

以PD1/PR-L1为基础的免疫疗法的成功强调了PD-L1在肿瘤进展中的重要作用，并提示我们急需通过深入了解PD-L1的表达调控机制，来开发新的方法以减弱PF-L1的功能。

ALK阳性的间变性大细胞淋巴瘤（ALK+ ALCL）由于ALK活性下游多条成瘤信号通路组成性激活而表达较高水平的PD-L1，使其成为研究肿瘤细胞中与PD-L1上调相关的信号通路的一个很好的模型。

研究人员通过CRISPR/Cas9文库筛选来研究ALK+ALCL中PD-L1调控所需的分子效应。研究人员发现PD-L1诱导依赖于STAT3的NPM-ALK癌蛋白活化，以及含有GRB2/SOS1的信号体，该信号体可激活MEK-ERK和PI3K-AKT信号通路。这些涉及STAT3和GRB2/SOS1的信号网络最终通过转录因子IRF4和BATF3作用于PD-L1基因增强子区域诱导PD-L1表达。

IRF4和BATF3对PD-L1上调至关重要，IRF4表达与原发性ALK+ ALCL组织中的PD-L1水平相关。当与PD-1阳性T细胞和NK细胞共培养时，靶向这些ALK+ ALCL中的成瘤信号通路可极大程度的抑制PD-L1介导肿瘤免疫逃逸的能力。

综上所述，本研究揭示了PD-L1上调表达的调控中心，加深了我们对驱动肿瘤免疫逃逸的分子回路的了解，并为改进免疫治疗干预策略提供新的方向。

原始出处：

Jing-Ping Zhang， et al. A novel model of controlling PD-L1 expression in ALK+ Anaplastic Large Cell Lymphoma revealed by CRISPR screening. Blood 2019 ：blood.2019001043； doi： https：//doi.org/10.1182/blood.2019001043

本文系梅斯医学（MedSci）原创编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779675, encodeId=b1931e79675de, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2311, encryptionId=f47023119c, topicName=ALK+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Aug 13 01:32:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702570, encodeId=42931e025702a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Mar 27 22:32:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255002, encodeId=b8a3125500287, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jun 05 06:32:00 CST 2019, time=2019-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463678, encodeId=212d14636e832, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Wed Jun 05 06:32:00 CST 2019, time=2019-06-05, status=1, ipAttribution=)]
    2019-08-13 tcm99hq

    #ALK+#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1779675, encodeId=b1931e79675de, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2311, encryptionId=f47023119c, topicName=ALK+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Aug 13 01:32:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702570, encodeId=42931e025702a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Mar 27 22:32:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255002, encodeId=b8a3125500287, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jun 05 06:32:00 CST 2019, time=2019-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463678, encodeId=212d14636e832, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Wed Jun 05 06:32:00 CST 2019, time=2019-06-05, status=1, ipAttribution=)]
    2020-03-27 marlenexl

    #细胞淋巴瘤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1779675, encodeId=b1931e79675de, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2311, encryptionId=f47023119c, topicName=ALK+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Aug 13 01:32:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702570, encodeId=42931e025702a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Mar 27 22:32:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255002, encodeId=b8a3125500287, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jun 05 06:32:00 CST 2019, time=2019-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463678, encodeId=212d14636e832, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Wed Jun 05 06:32:00 CST 2019, time=2019-06-05, status=1, ipAttribution=)]
    2019-06-05 smartjoy

    #PD-L1#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1779675, encodeId=b1931e79675de, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2311, encryptionId=f47023119c, topicName=ALK+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Aug 13 01:32:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702570, encodeId=42931e025702a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Fri Mar 27 22:32:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255002, encodeId=b8a3125500287, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Wed Jun 05 06:32:00 CST 2019, time=2019-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463678, encodeId=212d14636e832, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Wed Jun 05 06:32:00 CST 2019, time=2019-06-05, status=1, ipAttribution=)]
    2019-06-05 huangdf

    #变性#

    0

相关资讯

Nat Commun：食管鳞状细胞癌治疗新的见解

食管鳞状细胞癌（ESCC）治疗选择有限，研究表明，具有高BRCA1 / 2特征负荷的肿瘤对胰腺癌和乳腺癌中的铂疗法更敏感，这提出了ESCC中类似的突变模式可能有助于治疗不能手术的患者。此外，基于基因组学数据选择药物已经在个性化和靶向治疗的早期研究中产生了有希望的结果。一些靶向药物已用于ESCC，例如吉非替尼（EGFR抑制剂），Dovitinib（FGFR1抑制剂）和PD-L1阻断剂。然而，只有一小

Cell : PD-1靶点的境外战场-肿瘤外泌体与免疫治疗

Robert Blelloch认为免疫细胞在淋巴系统已经受到来自肿瘤细胞外泌体的免疫抑制。淋巴系统是免疫细胞激活的场所，肿瘤细胞分泌的外泌体可进入淋巴系统或从血液循环进入淋巴结。如果肿瘤细胞分泌的外泌体带有免疫抑制蛋白PD-L1，就可以使免疫细胞失活，并进一步阻止免疫细胞识别和杀伤肿瘤细胞。关于该远端失活机理的研究结果发表在2019年4月4日Cell期刊上，论文标题为“Suppression of

Lancet：Pembrolizumab可单药治疗低PD-L1 TPS的晚期非小细胞肺癌

Pembrolizumab（一种PD-1受体的单克隆抗体，美国上市商品名Keytruda，中文名帕博利珠）作为一线单药治疗可提高PD-L1肿瘤比例评分（TPS）≥50%的未治疗过的已转移的非小细胞肺癌患者的总体存活率和无进展存活率。现研究人员对采用Pembrolizumab治疗PD-L1 TPS≥1%的患者的总体存活率进行评估。研究人员在32个国家的214个医疗中心开展一随机的开放性的3期试验，招

SYNB1891与PD-L1检查点抑制剂联合治疗晚期实体瘤

Synlogic制药公司近日宣布，将与罗氏制药开展新的临床合作，以探索Synlogic的SYNB1891（一种双重免疫激活剂）与罗氏制药的PD-L1检测点抑制剂atezolizumab联合用于晚期实体瘤的有效性和安全性。Synlogic预计将于2019年下半年向FDA提交SYNB1891的研究性新药申请（IND）。

Blood：PD-1/PD-L1和p53缺失协同促进弥漫性大B细胞淋巴瘤进展

难治性或复发性弥漫性大B细胞淋巴瘤(DLBCL)常与活化的B细胞样(ABC)亚型和驱动NF-kB的固有性激活和影响B细胞的终末分化的基因突变相关。

Cell：刷新认知！癌细胞竟会放出“无人攻击机”，远程破坏免疫系统总部

今天，顶尖学术期刊《细胞》上发表了一篇重量级的论文。来自加州大学旧金山分校（UCSF）的科学家们发现，我们现有关于癌症免疫疗法的认知，很有可能是不完善的……其实不用这些科学家提醒，我们就知道现在的免疫疗法存在短板。“在黑色素瘤等最佳治疗案例中，免疫检查点抑制剂也只能对20%-30%的患者生效。在类似于前列腺癌等其他癌症里，缓解率只有个位数，”本研究的负责人Robert Blelloch教授说道：“